Hexahydrocannabinol (HHC) and Δ
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 Apr 2024
22 Apr 2024
Historique:
received:
21
11
2023
accepted:
03
04
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
22
4
2024
Statut:
epublish
Résumé
The Cannabis sativa plant has been used for centuries as a recreational drug and more recently in the treatment of patients with neurological or psychiatric disorders. In many instances, treatment goals include relief from posttraumatic disorders, anxiety, or to support treatment of chronic pain. Ligands acting on cannabinoid receptor 1 (CB1R) are also potential targets for the treatment of other health conditions. Using an evidence-based approach, pharmacological investigation of CB1R agonists is timely, with the aim to provide chronically ill patients relief using well-defined and characterized compounds from cannabis. Hexahydrocannabinol (HHC), currently available over the counter in many countries to adults and even children, is of great interests to policy makers, legal administrators, and healthcare regulators, as well as pharmacologists. Herein, we studied the pharmacodynamics of HHC epimers, which activate CB1R. We compared their key CB1R-mediated signaling pathway activities and compared them to the pathways activated by Δ
Identifiants
pubmed: 38649680
doi: 10.1038/s41598-024-58845-7
pii: 10.1038/s41598-024-58845-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9181Subventions
Organisme : Czech Science Foundation
ID : 21-02371S
Organisme : Institute of Molecular Genetics
ID : RVO68378050
Organisme : Ministry of Interior of the Czech Republic
ID : VK01010212
Informations de copyright
© 2024. The Author(s).
Références
Mechoulam, R. Cannabinoids as Therapeutic Agents 1–19 (CRC Press, 1986).
ElSohly, M. A. & Slade, D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 78, 539–548. https://doi.org/10.1016/j.lfs.2005.09.011 (2005).
doi: 10.1016/j.lfs.2005.09.011
pubmed: 16199061
Radwan, M. M., Chandra, S., Gul, S. & ElSohly, M. A. Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules https://doi.org/10.3390/molecules26092774 (2021).
doi: 10.3390/molecules26092774
pubmed: 34299506
pmcid: 8306967
Casati, S. et al. Hexahydrocannabinol on the light cannabis market: The latest “new” entry. Cannabis Cannabinoid https://doi.org/10.1089/can.2022.0253 (2022).
doi: 10.1089/can.2022.0253
Ujvary, I. et al. Hexahydrocannabinol (HHC) and related substances. 1–106 (2023).
Qureshi, M. N., Kanwal, F., Afridi, M. & Akram, M. Estimation of biologically active cannabinoids in Cannabis indica by gas chromatography-mass spectrometry (GC-MS). World Appl. Sci. J. 19, 918–923. https://doi.org/10.5829/idosi.wasj.2012.19.07.1922 (2012).
doi: 10.5829/idosi.wasj.2012.19.07.1922
Gaoni, Y. & Mechoulam, R. Isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron 22, 1481. https://doi.org/10.1016/S0040-4020(01)99446-3 (1966).
doi: 10.1016/S0040-4020(01)99446-3
Reggio, P. H., Greer, K. V. & Cox, S. M. The importance of the orientation of the C9 substituent to cannabinoid activity. J. Med. Chem. 32, 1630–1635. https://doi.org/10.1021/jm00127a038 (1989).
doi: 10.1021/jm00127a038
pubmed: 2738895
Mechoulam, R. et al. Stereochemical requirements for cannabinoid activity. J. Med. Chem. 23, 1068–1072. https://doi.org/10.1021/jm00184a002 (1980).
doi: 10.1021/jm00184a002
pubmed: 7420350
Adams, R. et al. Structure of cannabidiol. VIII. Position of the double bonds in cannabidiol. Marihuana activity of tetrahydro-cannabinols. J. Am. Chem. Soc. 62, 2566–2567. https://doi.org/10.1021/ja01866a510 (1940).
doi: 10.1021/ja01866a510
Russo, F. et al. Synthesis and pharmacological activity of the epimers of hexahydrocannabinol (HHC). Sci. Rep. 13, 11061. https://doi.org/10.1038/s41598-023-38188-5 (2023).
doi: 10.1038/s41598-023-38188-5
pubmed: 37422571
pmcid: 10329643
Cristino, L. et al. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151, 955–968. https://doi.org/10.1016/j.neuroscience.2007.11.047 (2008).
doi: 10.1016/j.neuroscience.2007.11.047
pubmed: 18248904
Gray, R. A. & Whalley, B. J. The proposed mechanisms of action of CBD in epilepsy. Epilept. Disord. 22, 10–15. https://doi.org/10.1684/epd.2020.1135 (2020).
doi: 10.1684/epd.2020.1135
Penumarti, A. & Abdel-Rahman, A. A. The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure. J. Pharmacol. Exp. Ther. 349, 29–38. https://doi.org/10.1124/jpet.113.209213 (2014).
doi: 10.1124/jpet.113.209213
pubmed: 24431468
pmcid: 3965889
Villapol, S. Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. Cell Mol. Neurobiol. 38, 121–132. https://doi.org/10.1007/s10571-017-0554-5 (2018).
doi: 10.1007/s10571-017-0554-5
pubmed: 28975471
Zou, S. L. & Kumar, U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci. https://doi.org/10.3390/ijms19030833 (2018).
doi: 10.3390/ijms19030833
pubmed: 30597923
pmcid: 6337518
Mackie, K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. https://doi.org/10.1007/3-540-26573-2_10 (2005).
doi: 10.1007/3-540-26573-2_10
pubmed: 16596779
Castillo, P. E., Younts, T. J., Chavez, A. E. & Hashimotodani, Y. Endocannabinoid signaling and synaptic function. Neuron 76, 70–81. https://doi.org/10.1016/j.neuron.2012.09.020 (2012).
doi: 10.1016/j.neuron.2012.09.020
pubmed: 23040807
pmcid: 3517813
Shenoy, S. K. & Lefkowitz, R. J. beta-arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 32, 521–533. https://doi.org/10.1016/j.tips.2011.05.002 (2011).
doi: 10.1016/j.tips.2011.05.002
pubmed: 21680031
pmcid: 3159699
Rueda, D., Galve-Roperh, I., Haro, A. & Guzman, M. The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. 58, 814–820. https://doi.org/10.1124/mol.58.4.814 (2000).
doi: 10.1124/mol.58.4.814
pubmed: 10999952
Leo, L. M. & Abood, M. E. CB1 cannabinoid receptor signaling and biased signaling. Molecules https://doi.org/10.3390/molecules26175413 (2021).
doi: 10.3390/molecules26175413
pubmed: 34500853
pmcid: 8433814
Ibsen, M. S., Connor, M. & Glass, M. Cannabinoid CB1 and CB2 receptor signaling and bias. Cannabis Cannabinoid 2, 48–60. https://doi.org/10.1089/can.2016.0037 (2017).
doi: 10.1089/can.2016.0037
Marzullo, P. et al. Cannabidiol as the substrate in acid-catalyzed intramolecular cyclization. J. Nat. Prod. 83, 2894–2901. https://doi.org/10.1021/acs.jnatprod.0c00436 (2020).
doi: 10.1021/acs.jnatprod.0c00436
pubmed: 32991167
pmcid: 8011986
Hajkova, A. et al. SGIP1 alters internalization and modulates signaling of activated cannabinoid receptor 1 in a biased manner. Neuropharmacology 107, 201–214. https://doi.org/10.1016/j.neuropharm.2016.03.008 (2016).
doi: 10.1016/j.neuropharm.2016.03.008
pubmed: 26970018
Gazdarica, M. et al. SGIP1 modulates kinetics and interactions of the cannabinoid receptor 1 and G protein-coupled receptor kinase 3 signalosome. J. Neurochem. https://doi.org/10.1111/jnc.15569 (2021).
doi: 10.1111/jnc.15569
Levoye, A. et al. A broad G protein-coupled receptor internalization assay that combines SNAP-tag labeling, diffusion-enhanced resonance energy transfer, and a highly emissive terbium cryptate. Front. Endocrinol. https://doi.org/10.3389/fendo.2015.00167 (2015).
doi: 10.3389/fendo.2015.00167
Herkenham, M. et al. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 11, 563–583 (1991).
doi: 10.1523/JNEUROSCI.11-02-00563.1991
pubmed: 1992016
pmcid: 6575215
Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 87, 1932–1936. https://doi.org/10.1073/pnas.87.5.1932 (1990).
doi: 10.1073/pnas.87.5.1932
pubmed: 2308954
pmcid: 53598
Jimenez-Blasco, D. et al. Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature 583, 603–608. https://doi.org/10.1038/s41586-020-2470-y (2020).
doi: 10.1038/s41586-020-2470-y
pubmed: 32641832
Maccarrone, M. et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci. 36, 277–296. https://doi.org/10.1016/j.tips.2015.02.008 (2015).
doi: 10.1016/j.tips.2015.02.008
pubmed: 25796370
pmcid: 4420685
Marsicano, G. & Lutz, B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11, 4213–4225. https://doi.org/10.1046/j.1460-9568.1999.00847.x (1999).
doi: 10.1046/j.1460-9568.1999.00847.x
pubmed: 10594647
Haring, M., Marsicano, G., Lutz, B. & Monory, K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146, 1212–1219. https://doi.org/10.1016/j.neuroscience.2007.02.021 (2007).
doi: 10.1016/j.neuroscience.2007.02.021
pubmed: 17383106
Kirilly, E., Hunyady, L. & Bagdy, G. Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: Relevance for their role in depression and in the actions of CB1 receptor antagonists. J. Neural Transm. 120, 177–186. https://doi.org/10.1007/s00702-012-0900-1 (2013).
doi: 10.1007/s00702-012-0900-1
pubmed: 22990678
Hebert-Chatelain, E. & Marsicano, G. A new link between cannabinoids and memory—The mitochondria. M. S-Med. Sci. 33, 579–581. https://doi.org/10.1051/medsci/20173306007 (2017).
doi: 10.1051/medsci/20173306007
Joshi, N. & Onaivi, E. S. Endocannabinoid system components: Overview and tissue distribution. Adv. Exp. Med. Biol. 1162, 1–12. https://doi.org/10.1007/978-3-030-21737-2_1 (2019).
doi: 10.1007/978-3-030-21737-2_1
pubmed: 31332731
Ford, B. M. et al. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol. Res. 125, 161–177. https://doi.org/10.1016/j.phrs.2017.08.008 (2017).
doi: 10.1016/j.phrs.2017.08.008
pubmed: 28838808
pmcid: 5849406
Ahn, K. H., Mahmoud, M. M. & Kendall, D. A. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J. Biol. Chem. 287, 12070–12082. https://doi.org/10.1074/jbc.M111.316463 (2012).
doi: 10.1074/jbc.M111.316463
pubmed: 22343625
pmcid: 3320953
Dvorakova, M. et al. SGIP1 is involved in regulation of emotionality, mood, and nociception and modulates in vivo signalling of cannabinoid CB1 receptors. Br. J. Pharmacol. 178, 1588–1604. https://doi.org/10.1111/bph.15383 (2021).
doi: 10.1111/bph.15383
pubmed: 33491188
Durydivka, O., Mackie, K. & Blahos, J. SGIP1 in axons prevents internalization of desensitized CB1R and modifies its function. Front. Neurosci. https://doi.org/10.3389/fnins.2023.1213094 (2023).
doi: 10.3389/fnins.2023.1213094
pubmed: 37547151
pmcid: 10397514
Niehaus, J. L. et al. CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol. Pharmacol. 72, 1557–1566. https://doi.org/10.1124/mol.107.039263 (2007).
doi: 10.1124/mol.107.039263
pubmed: 17895407
Blume, L. C. et al. Cannabinoid receptor interacting protein 1a competition with beta-arrestin for CB1 receptor binding sites. Mol. Pharmacol. 91, 75–86. https://doi.org/10.1124/mol.116.104638 (2017).
doi: 10.1124/mol.116.104638
pubmed: 27895162
pmcid: 5267523
Martini, L. et al. Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. Faseb J. 21, 802–811. https://doi.org/10.1096/fj.06-7132com (2007).
doi: 10.1096/fj.06-7132com
pubmed: 17197383
Martini, L., Thompson, D., Kharazia, V. & Whistler, J. L. Differential regulation of behavioral tolerance to WIN55, 212–2 by GASP1. Neuropsychopharmacology 35, 1363–1373. https://doi.org/10.1038/npp.2010.6 (2010).
doi: 10.1038/npp.2010.6
pubmed: 20164830
pmcid: 2953419
Jarrahian, A., Watts, V. J. & Barker, E. L. D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther. 308, 880–886. https://doi.org/10.1124/jpet.103.057620 (2004).
doi: 10.1124/jpet.103.057620
pubmed: 14634050
Hudson, B. D., Hebert, T. E. & Kelly, M. E. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol. Pharmacol. 77, 1–9. https://doi.org/10.1124/mol.109.060251 (2010).
doi: 10.1124/mol.109.060251
pubmed: 19837905